A Mechanism Underpinning the Bioenergetic Metabolism-Regulating Function of Gold Nanocatalysts
- PMID: 37767608
- DOI: 10.1002/smll.202304082
A Mechanism Underpinning the Bioenergetic Metabolism-Regulating Function of Gold Nanocatalysts
Abstract
Bioenergetic deficits are known to be significant contributors to neurodegenerative diseases. Nevertheless, identifying safe and effective means to address intracellular bioenergetic deficits remains a significant challenge. This work provides mechanistic insights into the energy metabolism-regulating function of colloidal Au nanocrystals, referred to as CNM-Au8, that are synthesized electrochemically in the absence of surface-capping organic ligands. When neurons are subjected to excitotoxic stressors or toxic peptides, treatment of neurons with CNM-Au8 results in dose-dependent neuronal survival and neurite network preservation across multiple neuronal subtypes. CNM-Au8 efficiently catalyzes the conversion of an energetic cofactor, nicotinamide adenine dinucleotide hydride (NADH), into its oxidized counterpart (NAD+ ), which promotes bioenergy production by regulating the intracellular level of adenosine triphosphate. Detailed kinetic measurements reveal that CNM-Au8-catalyzed NADH oxidation obeys Michaelis-Menten kinetics and exhibits pH-dependent kinetic profiles. Photoexcited charge carriers and photothermal effect, which result from optical excitations and decay of the plasmonic electron oscillations or the interband electronic transitions in CNM-Au8, are further harnessed as unique leverages to modulate reaction kinetics. As exemplified by this work, Au nanocrystals with deliberately tailored structures and surfactant-free clean surfaces hold great promise for developing next-generation therapeutic agents for neurodegenerative diseases.
Keywords: bioenergy metabolism; catalytic therapeutics; gold nanocrystals; nanozymes; neurodegenerative diseases; neuroprotection.
© 2023 The Authors. Small published by Wiley-VCH GmbH.
Similar articles
-
The Evolving Use of Gold Nanoparticles as a Possible Reversal Agent for the Symptoms of Neurodegenerative Diseases: A Narrative Review.Cureus. 2024 Jul 18;16(7):e64846. doi: 10.7759/cureus.64846. eCollection 2024 Jul. Cureus. 2024. PMID: 39156432 Free PMC article. Review.
-
Protein Corona Composition of Gold Nanocatalysts.ACS Pharmacol Transl Sci. 2024 Mar 14;7(4):1169-1177. doi: 10.1021/acsptsci.4c00028. eCollection 2024 Apr 12. ACS Pharmacol Transl Sci. 2024. PMID: 38633595 Free PMC article.
-
Evidence of brain target engagement in Parkinson's disease and multiple sclerosis by the investigational nanomedicine, CNM-Au8, in the REPAIR phase 2 clinical trials.J Nanobiotechnology. 2023 Dec 13;21(1):478. doi: 10.1186/s12951-023-02236-z. J Nanobiotechnology. 2023. PMID: 38087362 Free PMC article. Clinical Trial.
-
Study protocol of RESCUE-ALS: A Phase 2, randomised, double-blind, placebo-controlled study in early symptomatic amyotrophic lateral sclerosis patients to assess bioenergetic catalysis with CNM-Au8 as a mechanism to slow disease progression.BMJ Open. 2021 Jan 11;11(1):e041479. doi: 10.1136/bmjopen-2020-041479. BMJ Open. 2021. PMID: 33431491 Free PMC article.
-
CNM-Au8: an experimental agent for the treatment of amyotrophic lateral sclerosis (ALS).Expert Opin Investig Drugs. 2023 Jul-Dec;32(8):677-683. doi: 10.1080/13543784.2023.2252738. Epub 2023 Sep 1. Expert Opin Investig Drugs. 2023. PMID: 37642362 Review.
Cited by
-
The Evolving Use of Gold Nanoparticles as a Possible Reversal Agent for the Symptoms of Neurodegenerative Diseases: A Narrative Review.Cureus. 2024 Jul 18;16(7):e64846. doi: 10.7759/cureus.64846. eCollection 2024 Jul. Cureus. 2024. PMID: 39156432 Free PMC article. Review.
-
Efficacy and safety of CNM-Au8 in amyotrophic lateral sclerosis (RESCUE-ALS study): a phase 2, randomised, double-blind, placebo-controlled trial and open label extension.EClinicalMedicine. 2023 Jun 8;60:102036. doi: 10.1016/j.eclinm.2023.102036. eCollection 2023 Jun. EClinicalMedicine. 2023. PMID: 37396808 Free PMC article.
-
Protein Corona Composition of Gold Nanocatalysts.ACS Pharmacol Transl Sci. 2024 Mar 14;7(4):1169-1177. doi: 10.1021/acsptsci.4c00028. eCollection 2024 Apr 12. ACS Pharmacol Transl Sci. 2024. PMID: 38633595 Free PMC article.
-
CNM-Au8 in Amyotrophic Lateral Sclerosis: The HEALEY ALS Platform Trial.JAMA. 2025 Feb 17;333(13):1138-49. doi: 10.1001/jama.2024.27643. Online ahead of print. JAMA. 2025. PMID: 40067821 Free PMC article.
-
Blueprint of Collapse: Precision Biomarkers, Molecular Cascades, and the Engineered Decline of Fast-Progressing ALS.Int J Mol Sci. 2025 Aug 21;26(16):8072. doi: 10.3390/ijms26168072. Int J Mol Sci. 2025. PMID: 40869392 Free PMC article. Review.
References
-
- S. Camandola, M. P. Mattson, EMBO J. 2017, 36, 1474.
-
- H. Fu, J. Hardy, K. E. Duff, Nat. Neurosci. 2018, 21, 1350.
-
- M. Mamelak, Neurosci. Biobehav. Rev. 2017, 75, 297.
-
- Y. J. Hou, S. Lautrup, S. Cordonnier, Y. Wang, D. L. Croteau, E. Zavala, Y. Q. Zhang, K. Moritoh, J. F. O'Connell, B. A. Baptiste, T. V. Stevnsner, M. P. Mattson, V. A. Bohr, Proc. Natl. Acad. Sci. U. S. A. 2018, 115, E1876.
-
- A. N. Long, K. Owens, A. E. Schlappal, T. Kristian, P. S. Fishman, R. A. Schuh, BMC Neurol. 2015, 15, 19.
Publication types
MeSH terms
Substances
Grants and funding
LinkOut - more resources
Full Text Sources
Medical
Research Materials